Iodine-125 brachytherapy treatment for newly diagnosed brain metastasis in non-small cell lung cancer: A biocentric analysis

作者：Lili Yang, Congxiao Wang, Wei Zhang, Shifeng Liu, Tiantian Xuan, Han Jiang, Xiaokun Hu, Man Hu, Huanting Li · 发表于：Frontiers in Oncology · 年份：2022 · DOI：10.3389/fonc.2022.1005876 · 被引用次数：7 · 研究领域：Brain Metastases and Treatment、Lung Cancer Research Studies、Glioma Diagnosis and Treatment

Purpose The aim of the present study is to evaluate the safety and efficacy of iodine-125 brachytherapy for newly diagnosed brain metastasis in patients with non-small cell lung cancer (NSCLC). Materials and methods The study included 158 NSCLC patients diagnosed with brain metastasis from December 2003 to August 2017. Ninety-nine patients underwent external beam radiotherapy (EBRT group), and 59 patients received iodine-125 brachytherapy ( 125 I group). In addition, the 6- and 12-month progression-free survival (PFS) rates and the 12- and 24-month overall survival (OS) rates were compared between the EBRT group and the 125 I group. Median OS and PFS were analyzed using the Kaplan−Meier method with a log-rank test. Results The 6-month PFS rate was significantly higher in the 125 I group ( p = 0.002) than in the EBRT group, while no differences were found in the 12-month PFS rate ( p = 0.184). Additionally, the 12- ( p = 0.839) and 24-month ( p = 0.284) OS rates were not significantly different between the two groups. No significant differences in median OS ( p = 0.525) or PFS ( p = 0.425) were found between the two groups. Conclusions Iodine-125 brachytherapy is an alternative therapy for patients unable to undergo surgical resection.